Research and Markets: US DNA-Based Diagnostic Test and Equipment Market Analysis & Directions

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/ca3f08/us_dnabased_diagn) has
announced the addition of the "US DNA-Based Diagnostic Test and Equipment Market
Analysis & Directions" report to their offering.

DNA-based diagnostics are established in laboratory medicine with many of the
top tests run for infectious disease. The U.S. market for DNA-based infectious
disease tests is today a $1.1 billion industry. Nucleic acid testing (NAT) is
used to screen blood supplies; DNA-based tests are rapidly emerging as an
oncology standard as well; and newer tests are more slowly developing as a way
to treat other non-infectious diseases such as chronic diseases and diseases of
aging. However, they still operate largely outside of core medical practice
today - which is the doctor's office and hospital lab. Evidence that DNA-based
testing can appreciably improve the quality of healthcare is still murky, but
policymakers and scientific researchers believe that DNA-based diagnostics (also
called genomics-based molecular diagnostics) will change the way medicine is
practiced in the coming decades.

This Fuji-Keizai USA report examines the key players and issues in
commercializing DNA-based diagnostics in the United States. It covers the market
for testing products for infectious diseases, human cancers and
pharmacogenomics, and the instrumentation needed to perform the tests. It
analyzes U.S. market structure and size by major product segments. It covers
distribution structure; development trends and technology advances; regulations
and policies for genetic privacy, insurance coverage and DNA counseling; and a
future market outlook through 2012 - including market drivers and obstacles.

The report contains profiles of 15 companies including U.S.-based public and
private companies: Abbott Molecular Diagnostics, Celera, Genomic Health, Myriad
Genetics, Gen-Probe and Life Technologies (formerly Applied Biosystems). For key
players such as Siemens Healthcare, BioMérieux and Qiagen, whose core business
operates in non-U.S. regions, we cover their U.S.-oriented activities and
product portfolios. Others covered: Novartis V&D, Becton Dickinson, Interleukin
Genetics, Hologic/Third Wave Technologies, and Decode. Most of the
market-leading companies cater to the traditional medical channel and regulatory
path, although companies having great success with largely unregulated
laboratory-developed tests also factor into this report. Newer companies selling
personal genomic scans directly to consumers are growing in number but are not
the primary focus here, although they are covered briefly in the section C ( 27
companies).

Key Topics Covered:

Section A: Market Condition

* Market Overview
* Market Trends, 2008-2010
* Market Share by Product Segment of Surveyed Companies
* Distribution Structure
* New Product Development Trends
* Technology Character in DNA Diagnostic Product Development
* Future of Market
* Issues and Strategy for the DNA-Based Diagnostic and Test Business

Section B: Company Case Studies (15 Companies)

* Company In-Brief
* Revenue by Business Segment (DNA-based Diagnostics and Tests, Drugs, Medical
Equipment, etc.)
* Product Revenue Forecasts, 2007-2009
* Most Important Product for Sales and Marketing Spending - and Key Reason for
Spending on Product
* Distribution Policy
* R&D Activity
* Technology Trends
* New Product Development Activity
* Profitability
* Business Policies
* Market Trends (Roadmap): Future DNA Diagnostic and Test Market Outlook

Section C: Additional Companies in DNA-based Diagnostics, by Market Segment
Common Research Item

* Location/Contact Information
* URL
* Private or Public
* Revenue
* Current Product
* Developing Product & Application
* Technology, R&D and Commercialization
* Strategic Alliance and Partner

For more information visit
http://www.researchandmarkets.com/research/ca3f08/us_dnabased_diagn

Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

Copyright Business Wire 2009